Dicerna and Kyowa Kirin form RNAi collaboration
This article was originally published in Scrip
Executive Summary
The privately held US biotech company Dicerna Pharmaceuticals and Kyowa Hakko Kirin of Japan have entered into a collaboration and licence agreement for the R&D and commercialisation of RNAi drugs and delivery systems for oncology targets.